The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 12, 2022

Filed:

Jan. 31, 2018
Applicant:

Temple University of the Commonwealth System of Higher Education, Philadelphia, PA (US);

Inventors:

Kamel Khalili, Bala Cynwyd, PA (US);

Wenhui Hu, Cherry Hill, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/46 (2006.01); C12N 15/11 (2006.01); A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01); C12N 9/22 (2006.01);
U.S. Cl.
CPC ...
A61K 38/465 (2013.01); A61K 9/0034 (2013.01); A61K 35/12 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12N 15/111 (2013.01); C12N 2310/20 (2017.05); C12N 2320/30 (2013.01); C12N 2740/16063 (2013.01); C12Y 301/21 (2013.01);
Abstract

A method of treating a subject having a retroviral infection, by administering to the subject a therapeutically effective amount of a composition comprising a vector encoding a CRISPR-associated endonuclease and at least two guide RNAs, wherein the guide RNAs are complementary to two target sequences spanning from the 5'- to 3′-LTRs of the sequence in the retrovirus, and eradicating the retroviral infection. A method of immunizing a subject at risk of retroviral infection, by administering a prophylactically effective amount of a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of proviral DNA of a retrovirus to the subject, and preventing retroviral infection in the subject.


Find Patent Forward Citations

Loading…